Safety of Dobutamine-AtropineStress Myocardial Perfusion Scintigraphy

occurred in41 patients (3.8%).Independent predictors were infarctionscore (p < 0.01) and male gender (p < 0.05). ,AJI arrhythrniasterminated spontaneousty or after metoprolol adrnin stration. Conclusion: Dobutamine-atropine myocardial perfusion scintigraphy is a feasible method for the evaluation of coronary artery disease with a safety profile and feasibility comparable to those reported for dobutamine stress echocardiography. Patients withmore severe fixed perfusionabnormalitiesare at a higherriskof developing tachyarrhythrnias during the test. with and without tachyarrhyth mias on thallium and technetium studies.

[1]  J. Roelandt,et al.  Altered myocardial perfusion during dobutamine stress testing in silent versus symptomatic myocardial ischaemia assessed by quantitative MIBI SPET imaging , 1996, European Journal of Nuclear Medicine.

[2]  Jeroen J. Bax,et al.  Gender differences in the accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery disease. , 1997, The American journal of cardiology.

[3]  A. Salustri,et al.  Cardiac imaging for risk stratification with dobutamine-atropine stress testing in patients with chest pain. Echocardiography, perfusion scintigraphy, or both? , 1997, Circulation.

[4]  T. Marwick,et al.  Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years. , 1997, Journal of the American College of Cardiology.

[5]  M. Verani,et al.  Tolerance, hemodynamic changes, and safety of dobutamine stress perfusion imaging , 1996, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[6]  A. Salustri,et al.  Safety and feasibility of dobutamine-atropine stress echocardiography in patients with ischemic left ventricular dysfunction. , 1996, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[7]  J. Cornel,et al.  Prognostic significance of normal dobutamine-atropine stress sestamibi scintigraphy in women with chest pain. , 1996, The American journal of cardiology.

[8]  J. Roelandt,et al.  Dobutamine-induced hypoperfusion without transient wall motion abnormalities: less severe ischemia or less severe stress? , 1996, Journal of the American College of Cardiology.

[9]  Elliot A. Shefrin,et al.  Prevalence and prognostic significance of exercise-induced supraventricular tachycardia in apparently healthy volunteers. , 1995, The American journal of cardiology.

[10]  J. Leppo,et al.  Safety of dipyridamole testing in 73,806 patients: The Multicenter Dipyridamole Safety Study , 1995, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[11]  M. Cerqueira,et al.  Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. , 1994, Journal of the American College of Cardiology.

[12]  T. Marwick,et al.  Optimal use of dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both? , 1993, Journal of the American College of Cardiology.

[13]  T. Ryan,et al.  Symptoms, Adverse Effects, and Complications Associated With Dobutamine Stress. Echocardiography Experience in 1118 Patients , 1993, Circulation.

[14]  M. Verani,et al.  Dobutamine thallium-201 tomography for evaluating patients with suspected coronary artery disease unable to undergo exercise or vasodilator pharmacologic stress testing. , 1993, Journal of the American College of Cardiology.

[15]  D. Pennell,et al.  Dobutamine thallium myocardial perfusion tomography. , 1991, Journal of the American College of Cardiology.